Access to anti-retroviral drugs, male in Sub-Saharan Africa
Sub-Saharan Africa: Access to anti-retroviral drugs, male was 79.8% in 2024. ◆ Volatile
Access to anti-retroviral drugs, male in Sub-Saharan Africa, 2000–2024
Source: UNAIDS estimates. Measured in %.
Analysis
In 2024, access to anti-retroviral drugs, male in Sub-Saharan Africa stood at 79.8%. That is the highest value across all 25 years on record.
That represents a change of up 4.6% on the previous year and up 103.2% over ten years.
Over the whole period, access to anti-retroviral drugs, male in Sub-Saharan Africa peaked at 79.8% in 2024 and was at its lowest, 0.0%, in 2000.
The series is highly variable year to year, so single readings are best treated with caution.
Access to anti-retroviral drugs, male in Sub-Saharan Africa, year by year
| Year | % | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.1% | — |
| 2002 | 0.1% | +57.5% |
| 2003 | 0.7% | +461.2% |
| 2004 | 1.8% | +178.4% |
| 2005 | 3.9% | +113.3% |
| 2006 | 6.8% | +74.5% |
| 2007 | 10.4% | +53.3% |
| 2008 | 14.5% | +39.7% |
| 2009 | 18.6% | +28.7% |
| 2010 | 22.6% | +21.5% |
| 2011 | 26.4% | +16.7% |
| 2012 | 30.5% | +15.4% |
| 2013 | 35.2% | +15.5% |
| 2014 | 39.3% | +11.6% |
| 2015 | 44.0% | +12.2% |
| 2016 | 48.8% | +10.9% |
| 2017 | 54.5% | +11.6% |
| 2018 | 57.9% | +6.2% |
| 2019 | 62.4% | +7.8% |
| 2020 | 66.5% | +6.6% |
| 2021 | 69.9% | +5.1% |
| 2022 | 73.8% | +5.5% |
| 2023 | 76.3% | +3.4% |
| 2024 | 79.8% | +4.6% |
Biggest year-on-year movements
Years where Access to anti-retroviral drugs, male in Sub-Saharan Africa changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2003 | +461.2% | 0.1% | 0.7% |
| 2004 | +178.4% | 0.7% | 1.8% |
| 2005 | +113.3% | 1.8% | 3.9% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 5.7% | 0.0% | 18.6% | 10 |
| 2010s | 42.2% | 22.6% | 62.4% | 10 |
| 2020s | 73.2% | 66.5% | 79.8% | 5 |
Countries ranked near Sub-Saharan Africa
More gender data for Sub-Saharan Africa
- Child population (UN estimates and projections) 552,879 (2030)
- Child population (UN estimates and projections) (0-14), annual growth 1.42 % change on previous year (2030)
- Population 875,918 (2030)
- Working-age population (UN estimates and projections) 875,918 (2030)
- Population (UN estimates and projections), annual growth rate 2.84 % change on previous year (2030)
- Inactivity rate (ILO modelled estimates) 29.77 (2027)
- Child population (UN estimates and projections) (0-14), per capita 0.0004 units per person (2025)
- Population (UN estimates and projections), per capita 0.0006 units per person (2025)
- Labor force, female 247.09 million (2025)
- Labor force, female, per capita 0.187 units per person (2025)
Frequently asked questions
- What is access to anti-retroviral drugs, male in Sub-Saharan Africa?
- Access to anti-retroviral drugs, male in Sub-Saharan Africa was 79.8% in 2024, according to UNAIDS estimates.
- What is the highest access to anti-retroviral drugs, male recorded in Sub-Saharan Africa?
- The highest recorded value was 79.8% in 2024.
- What is the lowest access to anti-retroviral drugs, male recorded in Sub-Saharan Africa?
- The lowest recorded value was 0.0% in 2000.
- How does Sub-Saharan Africa rank for access to anti-retroviral drugs, male?
- Sub-Saharan Africa ranks 7th out of 19 groups with data for 2024.
- Is access to anti-retroviral drugs, male rising or falling in Sub-Saharan Africa?
- Over the last ten years it is up 103.2%. The long-run trend across the full record is volatile.
- Where does this Sub-Saharan Africa data come from?
- The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.